Acanthosis Nigricans

What is Acanthosis Nigricans?

Acanthosis nigricans describes hyperpigmented, velvety, and often symmetric plaques that manifest primarily on the posterior neck, axillae, and skin folds. This cutaneous marker most frequently appears in individuals with obesity, insulin resistance, or type 2 diabetes, representing an early clinical clue to dysregulated glucose metabolism. Early recognition of these lesions can prompt metabolic screening, allowing earlier intervention for underlying endocrine or oncologic processes.

What causes Acanthosis Nigricans?

Hyperinsulinemia drives keratinocyte and dermal fibroblast proliferation via insulin-like growth factor receptors, producing the characteristic epidermal thickening and hyperkeratosis of acanthosis nigricans. Key risk factors include obesity, metabolic syndrome, and polycystic ovary syndrome. In adults, abrupt onset or extensive involvement raises concern for paraneoplastic forms linked to gastrointestinal adenocarcinomas. Certain genetic syndromes and medications (e.g., nicotinic acid and corticosteroids) can also amplify insulin signaling or directly stimulate melanocyte activity, contributing to the skin changes.

What are the signs and symptoms of Acanthosis Nigricans?

The clinical presentation features sharply demarcated plaques with a velvety texture, frequently involving the posterior neck, axillae, groin, and occasionally mucous membranes. Patients may note mild pruritus but seldom pain. In individuals with obesity, the sign often appears gradually and correlates with worsening insulin resistance, whereas malignant cases typically progress rapidly and involve mucosa or atypical sites. When evaluating these plaques, differentiate them from other hyperpigmented or thickened dermatoses, such as confluent and reticulated papillomatosis or epidermal nevus, based on their characteristic velvety texture, symmetry, and predilection for intertriginous areas, which helps avoid misdiagnosis. A clinical atlas of neck and axillary lesions enhances recognition and reduces diagnostic delay.

How is the cause of Acanthosis Nigricans diagnosed?

Diagnosis relies on comprehensive history, physical examination, and targeted laboratory workup to identify underlying metabolic, endocrine, or neoplastic drivers of acanthosis nigricans. Screen for insulin resistance primarily with fasting glucose and hemoglobin A1c, though insulin or C-peptide levels may be considered in selected cases. Also evaluate for endocrinopathies such as hypothyroidism and Cushing syndrome with appropriate hormonal panels. When suspicion for malignancy arises—particularly with sudden onset or involvement of palms and mucosa—image the abdomen and pelvis and consider upper endoscopy. Skin biopsy, showing papillomatosis, hyperkeratosis, and basal layer hyperpigmentation, remains reserved for atypical presentations or when ruling out mimickers.

How is Acanthosis Nigricans treated?

Management targets the underlying etiology. Weight loss and improved glycemic control reduce insulin levels and often diminish plaques of acanthosis nigricans over months. In paraneoplastic cases, tumor-directed therapy may yield regression, whereas topical agents (keratolytics, retinoids) and chemical peels provide symptomatic relief for persistent lesions. Monitor affected individuals for progression or signs of malignancy and coordinate care with endocrinology or oncology when systemic diseases are confirmed to ensure comprehensive management.

What are the most important facts to know about Acanthosis Nigricans?

• Recognition of acanthosis nigricans enables early detection of insulin resistance and associated metabolic disorders.
• Hyperinsulinemia and growth factor signaling drive the epidermal proliferation seen in acanthosis nigricans.
• The characteristic velvety plaques appear on flexural surfaces and must be distinguished from other causes of hyperpigmentation or skin thickening that lack the insulin-resistance association of acanthosis nigricans.
• Diagnostic evaluation focuses on metabolic testing with escalation to imaging or biopsy when malignancy is suspected.
• Treatment prioritizes weight reduction, glycemic control, and addressing any underlying malignancy, supplemented by topical therapies for symptom relief.